stockportfolio.pro
CRL vs GMED: Which Stock Is the Better Buy?
Charles River Laboratories International, Inc. and Globus Medical, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — CRL vs GMED, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Charles River Laboratories International, Inc. (CRL) | Globus Medical, Inc. (GMED) | |
|---|---|---|
| Market cap | $11.1B | $11.0B |
| Revenue (latest FY) | $4.02B | $2.94B |
| Net income (latest FY) | $-144.34M | $537.87M |
| Revenue growth (5y CAGR) | 6.5% | 30.1% |
| Net margin | -3.6% | 18.3% |
| Return on equity | -4.6% | 11.8% |
| P/E ratio | — | 18.9 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 9 | 10 |
| Positive free cash flow | Yes | Yes |
See the full CRL vs GMED breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open CRL's full financials → Open GMED's full financials →More comparisons
Frequently asked questions
Which is bigger, CRL or GMED?
Charles River Laboratories International, Inc. is larger by market capitalization — $11.1B versus $11.0B.
Which grows faster, CRL or GMED?
Over the last five fiscal years, Globus Medical, Inc. grew revenue faster — 30.1%/yr versus 6.5%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.
Keep exploring
CRL fundamentals → · GMED fundamentals → · All 1,500+ companies → · Free screener →